首页> 外文期刊>Urology >Predictability of PSA failure in prostate cancer by computerized cytometric assessment of tumoral cell proliferation.
【24h】

Predictability of PSA failure in prostate cancer by computerized cytometric assessment of tumoral cell proliferation.

机译:通过计算机对肿瘤细胞增殖的细胞计数评估,可预测前列腺癌PSA衰竭的可能性。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: To evaluate the relationship of DNA ploidy and cell proliferation (CP) with Gleason score (GS) and clinical outcome in prostate cancer. METHODS: Sixteen patients with benign prostatic hyperplasia (BPH) and 65 patients with prostate cancer classified by GS (four groups: 2 to 4, 5 to 6, 7, and 8 to 10) were studied. All patients with carcinoma underwent prostatectomy and were separated into prostate-specific antigen (PSA) failure and nonfailure groups (failure if PSA 0.1 ng/mL or more three times after surgery). Tumoral CP (Ki-67 inmunostaining and SG2M phase) and DNA ploidy were evaluated by computerized cytometry. RESULTS: BPH were diploid with low CP (8% SG2M cells or less). Carcinomas were either diploid with high CP (greater than 8% SG2M cells) or aneuploid. CP was significantly higher (P <0.001) in tumors with GS 7 or greater than in tumors with GS less than 7 (mean percent Ki-67 cells 18.3% versus 7.8%, respectively). PSA failure increased with GS (7.1% in GS 2 to 4, 21% in GS 5 to 6, 28.6% in GS 7, and 50% in GS 8 to 10), as well as with aneuploidy (18.5% in diploid tumors versus 72.7% in aneuploid tumors). Those experiencing PSA failure had significantly higher (P <0.001) CP than those not failing (mean percent Ki-67 cells 24% and mean percent SG2M 30.4% versus 8.7% and 13.5%, respectively). Cox regression analysis showed GS, DNA ploidy, Ki-67, and SG2M to each be univariately prognostic for time to PSA failure; however, Ki-67 and SG2M were more highly significant (P <0.0001 for both) than GS (P = 0.007) or DNA ploidy (P = 0.002). After adjusting for either SG2M or Ki-67 measures of CP, neither ploidy nor GS contained additional prognostic value. CONCLUSIONS: Tumor CP and DNA ploidy can be reliably determined in prostate cancer by computerized cytometry. On the basis of our preliminary results, CP correlates well with GS and predicts PSA failure better than DNA ploidy or GS.
机译:目的:评估前列腺癌中DNA倍性和细胞增殖(CP)与格里森评分(GS)和临床结局的关系。方法:研究了16例按GS分类的良性前列腺增生(BPH)患者和65例前列腺癌患者(四组:2至4、5至6、7和8至10)。所有患有癌的患者均接受前列腺切除术,并分为前列腺特异性抗原(PSA)衰竭和非失败组(如果PSA 0.1 ng / mL或手术后三次以上失败)。通过计算机流式细胞术评估肿瘤CP(Ki-67免疫染色和SG2M期)和DNA倍性。结果:BPH为低CP(8%SG2M细胞或更少)的二倍体。癌是具有高CP(大于8%SG2M细胞)的二倍体或非整倍体。 GS≥7的肿瘤中的CP明显高于(GS <7)(GS小于7的肿瘤中(分别为18.3%和7.8%的Ki-67细胞百分比))。 PSA失败的发生率随着GS(GS 2至4的7.1%,GS 5至6的21%,GS 7的28.6%和GS 8-10的50%)以及非整倍性(二倍体肿瘤为18.5%)而增加在非整倍体肿瘤中占72.7%)。 PSA失败者的CP明显高于未失败者(P <0.001)(平均Ki-67细胞百分比为24%,SG2M平均百分比分别为30.4%和8.7%和13.5%)。 Cox回归分析显示GS,DNA倍性,Ki-67和SG2M对PSA衰竭的时间均具有单变量预后。然而,Ki-67和SG2M比GS(P = 0.007)或DNA倍性(P = 0.002)的意义更为显着(两者均P <0.0001)。在调整SG2M或CP的Ki-67量度后,倍性和GS均没有附加的预后价值。结论:可通过计算机细胞术可靠地确定前列腺癌中的肿瘤CP和DNA倍性。根据我们的初步结果,CP与GS有很好的相关性,并且预测PSA的失败要优于DNA倍性或GS。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号